Latest Insider Transactions at Mirum Pharmaceuticals, Inc. (MIRM)
This section provides a real-time view of insider transactions for Mirum Pharmaceuticals, Inc. (MIRM). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Mirum Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Mirum Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 23
2020
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Open market or private purchase
|
Indirect |
5,000
+1.23%
|
$90,000
$18.68 P/Share
|
|
Dec 23
2020
|
Ian Clements Chief Financial Officer |
BUY
Open market or private purchase
|
Direct |
2,470
+14.62%
|
$44,460
$18.6 P/Share
|
|
Nov 10
2020
|
Christopher Peetz CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,371
+50.0%
|
$20,565
$15.27 P/Share
|
|
Nov 10
2020
|
Ian Clements Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,371
+20.34%
|
$20,565
$15.27 P/Share
|
|
Nov 10
2020
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,275
+3.8%
|
$19,125
$15.27 P/Share
|
|
Nov 10
2020
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
822
+1.07%
|
$12,330
$15.27 P/Share
|
|
Nov 10
2020
|
Peter Radovich PRESIDENT AND COO |
BUY
Grant, award, or other acquisition
|
Direct |
861
+19.72%
|
$12,915
$15.27 P/Share
|
|
Nov 10
2020
|
Pamela Vig CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
595
+21.23%
|
$8,925
$15.27 P/Share
|
|
Oct 30
2020
|
Edwin Jonathan Tucker Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+44.64%
|
$175,000
$7.7 P/Share
|
|
Sep 10
2019
|
Lara Longpre CHIEF DEVELOPMENT OFFICER |
BUY
Open market or private purchase
|
Direct |
965
+0.91%
|
$9,650
$10.64 P/Share
|
|
Jul 22
2019
|
James E Flynn > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
332,000
+29.39%
|
$4,980,000
$15.0 P/Share
|
|
Jul 22
2019
|
James E Flynn > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
3,116,912
+50.0%
|
-
|
|
Jul 22
2019
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
575,000
+19.04%
|
$8,625,000
$15.0 P/Share
|
|
Jul 22
2019
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
1,870,147
+50.0%
|
-
|